Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape

Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial.

Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.

Radiofrequency deep hyperthermia combined with chemotherapy in the treatment of advanced non-small cell lung cancer

[Vaccines for the treatment of non-small cell lung cancer]

Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients‘ preference-based study (PPPS)

Recombinant Newcastle disease virus expressing human IFN-λ1 (rL-hIFN-λ1)-induced apoptosis of A549 cells is connected to endoplasmic reticulum stress pathways

Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.

Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC

Increased cycles of DC/CIK immunotherapy decreases frequency of Tregs in patients with resected NSCLC